Treatment of negative and cognitive symptoms of schizophrenia with D-serine

• US 6,162,827 A
• Filed: 12/16/1998
• Issued: 12/19/2000
• Est. Priority Date: 12/07/1995
• Status: Expired due to Term

• Current Assignee: Daniel Javitt
• Original Assignee: Daniel Javitt
• Inventors: Javitt, Daniel C.
• Primary Examiner(s): MacMillan, Keith D.
• Application Number:
  US09/212,273
• Time in Patent Office: 734 Days
• Field of Search: 514/561
• US Class Current: 514/561
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 39/02 Antidotes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The amino acid glycine in an administered amount of above 0.4 g/Kg/day is used for treating symptoms of psychosis and of schizophrenia.

Claims

1. A process for treating a human patient having a psychosis which comprises administering to said human D-serine.